Oral pazopanib improves sight in macular degeneration cases

Oral pazopanib improves sight in macular degeneration cases
Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration, according to a study published online Oct. 10 in JAMA Ophthalmology.

(HealthDay)—Oral pazopanib is well tolerated and improves mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a small, per-protocol, non-rescued population of patients with age-related macular degeneration (AMD), according to a study published online Oct. 10 in JAMA Ophthalmology.

Megan M. McLaughlin, from GlaxoSmithKline in King of Prussia, Pa., and colleagues conducted a 14-day, placebo-controlled, dose-rising study in 72 healthy participants (oral pazopanib tablets, 5 to 30 mg daily) and a 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD (15 mg daily).

The researchers found that oral pazopanib was well tolerated by all. Rescue therapy before day 29 was received by six of the 15 patients, all of whom had the CFH Y402H CC "high-risk" genotype for AMD. The other nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness. The association between the CFH Y402H T allele ("low risk" for AMD) trended toward improvement.

"It is postulated that CFH Y402H genotype may help predict which respond to pazopanib," the authors write.

Several authors disclosed financial ties to GlaxoSmithKline, which manufactures pazopanib and funded the study.

More information: Abstract
Full Text

Related Stories

Genotyping IDs long-term risk of macular degeneration

date Nov 13, 2012

(HealthDay)—Genotyping of two genetic risk alleles can be used to estimate the long-term risk of early and late age-related macular degeneration (AMD), but knowing the phenotype is important in assessing ...

GEN reports on ocular therapeutics targeting the retina

date Sep 10, 2012

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for si ...

Supplement aids age-related macular degeneration

date Mar 26, 2013

(HealthDay)—A supplement containing a combination of lutein, zeaxanthin, and ω-3 long-chain polyunsaturated fatty acids (LC-PUFAs) significantly benefits patients with age-related macular degeneration ...

Recommended for you

Lowering risk of a major eye disease

date May 20, 2015

Age-related macular degeneration (AMD), a chronic, progressive disease, is a leading cause of blindness among people aged 65 and older. Vision impairment due to advanced AMD significantly reduces quality ...

Age-related macular degeneration, mortality linked

date May 12, 2015

(HealthDay)—Age-related macular degeneration (AMD) is a predictor of poor survival, especially among women aged 80 years and older, according to a study published online May 4 in the Journal of the American Ge ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.